Tag Archives: David Brennan

AZ Celebrates Crestor Patent Win

The US District Court in Delaware upheld AstraZeneca’s patent for its blockbuster statin Crestor (rosuvastatin), ending a dispute that could have crippled the drugmaker’s billion-dollar cash cow. Crestor’s patent is not scheduled to expire until 2016. However, a group of generics firms had claimed that a substance patent (314) protecting one of the active ingredients […]
Posted in Legal | Also tagged , , , , , , | Leave a comment

AstraZeneca to Slash 8,000 More Jobs (Updated 2/3/10)

Last year, AstraZeneca announced the elimination of some 15,000 jobs. Last Thursday, the London-based company revealed that it plans to lay off another 8,000 by 2014—this despite global revenue growth of 4 percent for 2009. Much of the drive for this addition labor sculpting stems from AZ’s desire to streamline its R&D; the company will […]
Posted in Strategy | Also tagged , , , , , , , | 1 Comment
  • Categories

  • Meta